atrophic gastritis and gastric intestinal metaplasia
Two routes to the same atrophic stomach: H. pylori (antrum first, spreads proximally; most common) and autoimmune (corpus-only, antrum spared). GIM on a biopsy almost always means atrophy is present. Every patient: test for H. pylori, eradicate, confirm cure (AGA strong). Corpus atrophy → check iron and B12; autoimmune → also TSH, and endoscopy to look for type 1 gastric NETs. Surveillance is not routine for incidental GIM (AGA, very low certainty); offer it by shared decision when risk is high: extensive or incomplete GIM, first-degree relative with gastric cancer, immigrant from a high-incidence region (East Asia, Latin America, Eastern Europe). Advanced atrophy → endoscopy about every 3 years.
the two patterns
flowchart LR A[H. pylori chronic gastritis] --> B[atrophy: antrum and incisura first] B --> C[intestinal metaplasia] C --> D[dysplasia] D --> E[intestinal-type gastric adenocarcinoma] F[autoimmune: anti-parietal cell + anti-IF] --> G[corpus atrophy, antrum spared] G --> H[achlorhydria → ↑gastrin → ECL hyperplasia] H --> I[type 1 gastric NET] G --> J[iron deficiency, then B12 deficiency / pernicious anaemia] G --> C
| H. pylori atrophic gastritis | autoimmune gastritis | |
|---|---|---|
| distribution | antrum → spreads to corpus | corpus/fundus only, antrum spared |
| who | H. pylori-endemic regions, older, immigrants from high-risk countries | women, other autoimmunity (up to ⅓ of autoimmune thyroid disease), T1DM |
| gastrin | normal or modestly raised | markedly raised (loss of acid feedback) |
| main risks | adenocarcinoma | iron and B12 deficiency, type 1 NET, adenocarcinoma |
| serology | H. pylori positive (may have cleared) | anti-parietal cell (sensitive, not specific); anti-intrinsic factor (specific, <30% sensitive) |
- mechanism behind the deficiencies: acid is needed to release dietary non-haem iron; parietal cells make intrinsic factor. Iron deficiency appears years before B12 deficiency (up to half of corpus-predominant AG)
- pernicious anaemia = end-stage autoimmune gastritis
- progression to adenocarcinoma ~0.1–0.3%/year, similar to non-dysplastic Barrett’s oesophagus; higher with extent, severity and IM
the first endoscopy decides the risk
- diagnosis is histological: endoscopic pallor, visible vessels and lost folds are suggestive but subtle
- updated Sydney protocol: ≥5 biopsies, antrum/incisura and corpus in separate jars. Random biopsies in one jar can’t stage extent or separate the two patterns, which is why surveillance decisions after a single-jar “GIM” are hard
- OLGA/OLGIM stage III–IV = advanced (extensive, severe) → highest risk. Few North American pathologists report it routinely
- incomplete (colonic-type) GIM ~3× and extensive GIM ~2× the cancer risk of complete or antrum-limited GIM; first-degree relative with gastric cancer ~4.5×
- autoimmune pattern on histology → anti-parietal cell + anti-intrinsic factor antibodies to support it
management
every patient
- H. pylori: test (serology alone can’t confirm active infection) → eradicate → confirm cure with a non-serological test (UBT or stool antigen) → peptic ulcer disease and H. pylori
- eradication lowers gastric cancer incidence ~32% (RR 0.68; trials of infected people with and without GIM); the GIM-only subgroup is underpowered (RR 0.76, CI crosses 1). Atrophy can regress after eradication; established IM usually doesn’t
- corpus involvement (either cause): ferritin, B12; and conversely, think of atrophic gastritis in unexplained iron or B12 deficiency → iron deficiency, anaemia
- the cause doesn’t go away: replacement is long-term, and oral iron absorbs poorly without acid
autoimmune gastritis
- TSH at diagnosis and periodically; low threshold to look for T1DM and Addison’s when symptoms fit
- endoscopy to screen for type 1 NETs (incidence ~0.4–0.7%/year with corpus atrophy)
- <1 cm → endoscopic resection, then endoscopy every 1–2 years by burden
- 1–2 cm → EUS for depth and nodes
-
2 cm, beyond submucosa or node-positive → surgery (metastasis <10% when ≤2 cm, ~20% when larger)
- new pernicious anaemia without a recent endoscopy → endoscopy with mapping biopsies (ASGE: within 6 months; cancer risk highest in the first year). Surveillance interval after that: individualised (ESGE 3–5 years)
surveillance for gastric cancer
| situation | default | guideline |
|---|---|---|
| incidental GIM, no high-risk features | no routine surveillance | AGA 2020, conditional, very low certainty |
| GIM + incomplete type, extensive, first-degree relative, or high-incidence ancestry / immigration | shared decision for surveillance; if chosen, endoscopy with mapping biopsies every 3–5 years | AGA 2020 |
| GIM + nodularity, poor-quality index scope, or single-jar biopsies in a high-risk person | repeat endoscopy within 1 year to map extent, subtype, exclude prevalent cancer | AGA 2020 (patient preference; AGA advises against routine short-interval repeat for risk stratification alone) |
| advanced AG (OLGA/OLGIM III–IV, extensive) | consider endoscopy ~every 3 years (individualised) | AGA 2021 |
| dysplasia | GI referral for resection; outside this note | — |
No study compares surveillance with no surveillance for outcomes; the case rests on cohort data (~1.6% ten-year cancer risk with GIM overall) and on high-incidence-country data. In Canada, much of the higher risk sits in immigrants from East Asia, Latin America and Eastern Europe, which is where a surveillance discussion is worth having.
key points
- GIM is found in ~5% of upper endoscopies; most will never progress
- ASGE suggests stopping surveillance after two consecutive endoscopies without dysplasia
- pepsinogen I/II testing is used for screening in East Asia; not available routinely in Canada
- population gastric cancer screening isn’t recommended in low-incidence countries → cancer screening — Canadian guidelines
Prepared 2026-11-19. Not yet verified — check every number against the sources.